Acro Biomedical Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 24, 2021 at 12:34 am IST
Share
Acro Biomedical Co., Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 500,000. Operating loss was USD 793,320 compared to USD 62,771 a year ago. Net loss was USD 794,687 compared to USD 63,699 a year ago. Basic loss per share from continuing operations was USD 0.02. For the half year, sales was USD 599,500 compared to USD 687,964 a year ago. Operating loss was USD 850,311 compared to operating Income of USD 18,786 a year ago. Net loss was USD 854,181 compared to net income of USD 17,417 a year ago. Basic loss per share from continuing operations was USD 0.02.
Acro Biomedical Co., Ltd. is principally engaged in the business is the sale of cordyceps related products. The Company is focused on developing and marketing nutritional products that promote wellness and a healthy lifestyle. The Company's business consists of selling cordyceps related products that is used in traditional Chinese medicine. Cordyceps is a fungus, which is a combination of a caterpillar and a fungus, which is found at altitudes above 4500 meters (m) in Sikkim. The Company is involved in the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. It sells products in bulk to companies who may use the Company's products as ingredients in their products or sell the products they purchase from the Company to their own customers.
ACRO BIOMEDICAL CO., LTD. 
